Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs ResMed Inc. — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 337.6× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and ResMed Inc. pays a 1.16% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and ResMed Inc. for 51 Days on average.
| MSTZ | RMD | |
|---|---|---|
Market Cap | $94.46M | $31.89B |
Volume | 104,717,733 | 618,314 |
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $275.96 |
52-Week Low | $2.29 | $182.82 |
Typical Hold Time | 8 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $2.73, up 2.63% today, but technical indicators show a bearish trend with moving averages signaling caution. The stock lacks available fundamental data for key valuation and profitability metrics, making financial health assessment challenging. Recent ETF performance coverage highlights market volatility but provides no direct company-specific news.
The outlook is clouded by missing financials and bearish technicals. Investment opportunity hinges on future earnings visibility and competitive positioning. Key risks include potential weak fundamentals, market volatility, and lack of analyst coverage, requiring careful due diligence before consideration.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
